Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Health

Results: 8545-8556 of 9407

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2023

PR Newswire associated0

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

PR Newswire associated0

Medical Device First to Enter the European Market with Sustainable, Innovative Sterilization Approach with Chlorine Dioxide Gas

QPS Missouri is a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials in Springfield, Missouri, and has recently added a new safety laboratory, updated pharmacy, and clinical trial kit production facility. (Photo: Business Wire)

QPS Holdings, LLC Expands Operations in Springfield, Missouri

‘Orthodontic Treatments Using Directly 3D-Printed Clear Aligners’ published in the Journal of Clinical Orthodontics on October 2023 (Graphic: Business Wire)

‘AlignMiracle’ Makes Waves in the World of Direct Clear Aligner, Featured in the Prestigious International Clinical Journal, JCO

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Business Wire logo

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Business Wire logo

Inventia Life Science Announces Third Dimension Grant for 3D Cell Culture Research

XNK Therapeutics to present at DNB Nordic Healthcare Conference in Oslo

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

  • Prev Page
  • 1
  • 2
  • …
  • 712
  • 713
  • 714
  • …
  • 783
  • 784
  • Next Page

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us